Nā hualoaʻa haʻahaʻa o ka CD7-Targeted CAR-T Therapy no T-ALL a me T-LBL

Ua hōʻike ʻia kahi hoʻokolohua lapaʻau hou i nā holomua nui i ka mālama ʻana i ka relapsed a refractory T-cell acute lymphoblastic leukemia (T-ALL) a me T-cell lymphoblastic lymphoma (T-LBL) me ka hoʻohana ʻana i ka CD7-targeted chimeric antigen receptor (CAR) T cell therapy . ʻO ke aʻo ʻana, i alakaʻi ʻia e kahi hui mai ka Halemai Hebei Yanda Lu Daopei a me Lu Daopei Institute of Hematology, pili i nā maʻi 60 i loaʻa i hoʻokahi kaila o nā pūnaewele T anti-CD7 CAR (NS7CAR) koho kūlohelohe.

Hoʻoikaika nui nā hopena hoʻokolokolo. Ma ka lā 28, 94.4% o nā maʻi i loaʻa i ke kala piha hohonu (CR) i ka iwi iwi. Eia kekahi, ma waena o nā maʻi maʻi 32 me ka maʻi extramedullary, 78.1% i hōʻike i kahi pane maikaʻi, me 56.3% i loaʻa i ke kala piha a me 21.9% i loaʻa i ke kala ʻāpana. He 63.5% a me 53.7% ka nui o ke ola ana o na makahiki elua.

He mea kaulana kēia lāʻau lapaʻau no kāna ʻike palekana palekana, me ka cytokine release syndrome e kū nei ma 91.7% o nā maʻi (ka hapa nui o ka 1/2), a ʻike ʻia ka neurotoxicity i 5% o nā hihia. Eia kekahi, ua ʻike ʻia ka haʻawina ʻo ka poʻe maʻi i hoʻomau me ka hoʻohui ʻana i nā transplants ma hope o ka loaʻa ʻana o CR i ʻoi aku ka kiʻekiʻe o ka piʻi ʻana o ke ola ola ʻole i hoʻohālikelike ʻia me ka poʻe ʻaʻole.

Ke ʻimi nei kā mākou hui i ka hiki o ka CD7 CAR-T cell therapy me kā mākou huahana proprietary, e manaʻo ana e kōkua i ka holomua o ka mālama ʻana i nā maʻi maʻi T-cell.

Hōʻike kēia mau ʻike i ka hiki o ka CD7-targeted cell therapy e hāʻawi i ka manaʻolana hou no nā poʻe maʻi me ka refractory a i ʻole ka hoʻihoʻi hou ʻana o T-ALL a me T-LBL, e hōʻailona ana i kahi mea nui i ke kaua e kū nei i kēia mau maʻi paʻakikī.